| Biological Information | |
|---|---|
| Background Information: | Complex of N-terminal 6His-tagged recombinant, human full length p110α containing the mutation E542K and untagged, recombinant, full length human p85α. The E542K substitution is a somatic mutation in p110α that has been associated with tumors of the colon and brain. Combined in vitro and in vivo studies have shown that this mutation confers higher lipid kinase activity than wild type, and is able to induce oncogenic transformation. |
| Target Class: | Kinase |
| Family: | Lipid Kinase |
| Accession Number: | NM_006218.2 |
| Target Name: | PI3Kα/p85α |
| Target Aliases: | PIK3CA, PI3K, MGC142161, p110-alpha, MGC142163 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
PI3 Kinase (p110alpha(E542K)/p85alpha)
10 µg of PI3 Kinase (p110α(E542K)/p85α). Complex of N-terminal 6His-tagged recombinant, human full length p110α containing the mutation E542K and untagged, recombinant, full length human p85α.
Datasheets
14-782x Datasheet
View Document